INTRODUCTION: Relatively few studies have investigated pharmacological or behavioral treatment of smokeless tobacco (ST) users who do not have immediate quit plans. In this study, we compared a reduction treatment approach with an immediate cessation approach in a population of ST users who reported no immediate plans to quit. METHODS: Subjects randomly assigned to the immediate cessation condition set a quit date soon after enrollment and were offered 2 weeks of nicotine patch therapy to help in their cessation efforts. Subjects assigned to the ST reduction group were provided with their choice of either 4 mg nicotine lozenge or ST brand switching to help them reduce their ST use or levels of nicotine exposure, respectively. Quit date was 6 weeks after the onset of treatment. Follow-up was at 12 weeks and 26 weeks postenrollment and 26 weeks postquit. RESULTS: Both 7-day point prevalence abstinence and prolonged abstinence rates following the quit date were significantly higher in the immediate cessation group versus the reduction group at 12 and 26 weeks (all p values ≤ .04) and for prolonged abstinence at 6 months postquit (p = .002). Significant reductions in ST use among nonquitters were observed for both groups (p < .0001) with no differences between groups. CONCLUSION: Our study demonstrated that immediate cessation with an established quit date resulted in greater cessation success than a gradual reduction approach among ST users who do not have an immediate quit plan but are motivated to quit.
RCT Entities:
INTRODUCTION: Relatively few studies have investigated pharmacological or behavioral treatment of smokeless tobacco (ST) users who do not have immediate quit plans. In this study, we compared a reduction treatment approach with an immediate cessation approach in a population of ST users who reported no immediate plans to quit. METHODS: Subjects randomly assigned to the immediate cessation condition set a quit date soon after enrollment and were offered 2 weeks of nicotine patch therapy to help in their cessation efforts. Subjects assigned to the ST reduction group were provided with their choice of either 4 mg nicotine lozenge or ST brand switching to help them reduce their ST use or levels of nicotine exposure, respectively. Quit date was 6 weeks after the onset of treatment. Follow-up was at 12 weeks and 26 weeks postenrollment and 26 weeks postquit. RESULTS: Both 7-day point prevalence abstinence and prolonged abstinence rates following the quit date were significantly higher in the immediate cessation group versus the reduction group at 12 and 26 weeks (all p values ≤ .04) and for prolonged abstinence at 6 months postquit (p = .002). Significant reductions in ST use among nonquitters were observed for both groups (p < .0001) with no differences between groups. CONCLUSION: Our study demonstrated that immediate cessation with an established quit date resulted in greater cessation success than a gradual reduction approach among ST users who do not have an immediate quit plan but are motivated to quit.
Authors: S S Hecht; S G Carmella; M Chen; J F Dor Koch; A T Miller; S E Murphy; J A Jensen; C L Zimmerman; D K Hatsukami Journal: Cancer Res Date: 1999-02-01 Impact factor: 12.701
Authors: Margaret M Walsh; Joan F Hilton; James A Ellison; Lauren Gee; Margaret A Chesney; Scott L Tomar; Virginia L Ernster Journal: Addict Behav Date: 2003-08 Impact factor: 3.913
Authors: Andrew J Oliver; Joni A Jensen; Rachel I Vogel; Amanda J Anderson; Dorothy K Hatsukami Journal: Nicotine Tob Res Date: 2012-04-22 Impact factor: 4.244
Authors: Cathryn Glanton Holzhauer; Elizabeth E Epstein; Amy M Cohn; Barbara S McCrady; Fiona S Graff; Sharon Cook Journal: J Subst Abuse Treat Date: 2017-01-13